Get started
AMGEN DRNAMGEN DRNAMGEN DRN

AMGEN DRN

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals Bonds

AMGN34 chart


Full chart

Key facts today


Amgen's shares fell 2.5% to 2.8% after Eli Lilly reported positive trial results for its weight-loss drug orforglipron, impacting the market for obesity treatments.
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪868.79 B‬ BRL
Dividend yield (indicated)
2.34%
Price to earnings Ratio (TTM)
39,466.67
Basic EPS (TTM)
0.00 BRL
Net income (FY)
‪22.05 B‬ BRL
Revenue (FY)
‪179.15 B‬ BRL
Shares float
—
Beta (1Y)
0.012

About Amgen Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Robert A. Bradway
Website
amgen.com
Headquarters
Thousand Oaks
Founded
1980
ISIN
BRAMGNBDR004
FIGI
BBG002H1H201
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

AMGN34 news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

AMGN34 highest yielding bonds


AMGN5186584
Amgen Inc. 2.77% 01-SEP-2053
Yield to maturity
7.52%
Maturity date
Sep 1, 2053
AMGN5235280
Amgen Inc. 3.0% 15-JAN-2052
Yield to maturity
7.46%
Maturity date
Jan 15, 2052
US31162CS7
AMGEN 20/50
Yield to maturity
6.89%
Maturity date
Feb 21, 2050
US31162BP4
AMGEN 12/43
Yield to maturity
6.80%
Maturity date
May 15, 2043
AMGN5235282
Amgen Inc. 2.8% 15-AUG-2041
Yield to maturity
6.74%
Maturity date
Aug 15, 2041
US31162DG2
AMGEN 22/62
Yield to maturity
6.70%
Maturity date
Feb 22, 2062
AMGD
AMGEN 22/52
Yield to maturity
6.70%
Maturity date
Feb 22, 2052
AMGN4437315
Amgen Inc. 4.563% 15-JUN-2048
Yield to maturity
6.59%
Maturity date
Jun 15, 2048
US31162CR9
AMGEN 20/40
Yield to maturity
6.54%
Maturity date
Feb 21, 2040
AMGN4436563
Amgen Inc. 4.663% 15-JUN-2051
Yield to maturity
6.49%
Maturity date
Jun 15, 2051
US31162BZ2
AMGEN 15/45
Yield to maturity
6.47%
Maturity date
May 1, 2045

See all AMGN34 bonds 

Sparks


Curated watchlists where AMGN34 is featured.

See all sparks 


Check out other big names from the same industry as AMGN34.